• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

希腊的甲状腺乳头癌中 PI3K/Akt 通路的突变和免疫组化研究。

Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.

机构信息

1st Department of Pathology, Medical School, University of Athens, M. Asias 75, Athens, 11527, Greece.

出版信息

Endocr Pathol. 2010 Jun;21(2):90-100. doi: 10.1007/s12022-010-9112-0.

DOI:10.1007/s12022-010-9112-0
PMID:20186503
Abstract

PI3K/Akt signaling pathway plays critical role in many cell processes. There is indication that enhanced activation of PI3K/Akt cascade is implicated in thyroid tumors. Aim of this study was to evaluate the mutational status and expression of PI3K/Akt pathway mediators in papillary thyroid carcinoma in Greece. We evaluated the presence of mutations in PIK3CA (exons 9 and 20), AKT1 (exons 6-11), AKT2 (exons 6-11), AKT3 (exons 5-10), PTEN (exons 3-8), and PDPK1 (exons 4-10) genes in 83 papillary thyroid carcinomas by DNA sequencing. The expression levels of phospho-Akt and insulin-like growth factor I receptor (IGF-IR) were evaluated by immunohistochemistry. PIK3CA mutations were found in three samples. The analysis of AKT1 revealed one silent mutation in exon 9 (G726A) in 16 samples. One specimen carried an AKT3 mutation. One missense mutation was found in one sample in PTEN. No mutations were found in AKT2 and PDPK1. Increased levels of phosphorylated total Akt and IGF-IR were identified in some papillary cancers. Our findings indicate that PI3K/Akt signaling pathway is activated in some papillary tumors. However, mutations in genes coding most mediators of the pathway have not been proven to be the major modus of enhanced activation. These data suggest a potential role for PI3K/Akt-mediated signaling in papillary thyroid tumors.

摘要

PI3K/Akt 信号通路在许多细胞过程中发挥着关键作用。有迹象表明,PI3K/Akt 级联的激活增强与甲状腺肿瘤有关。本研究旨在评估希腊甲状腺乳头状癌中 PI3K/Akt 通路介质的突变状态和表达。我们通过 DNA 测序评估了 83 例甲状腺乳头状癌中 PIK3CA(外显子 9 和 20)、AKT1(外显子 6-11)、AKT2(外显子 6-11)、AKT3(外显子 5-10)、PTEN(外显子 3-8)和 PDPK1(外显子 4-10)基因的突变情况。通过免疫组织化学评估磷酸化 Akt 和胰岛素样生长因子 I 受体(IGF-IR)的表达水平。在三个样本中发现了 PIK3CA 突变。AKT1 的分析显示在 16 个样本中外显子 9 中的一个沉默突变(G726A)。一个标本携带 AKT3 突变。在一个样本中发现了一个 PTEN 的错义突变。在 AKT2 和 PDPK1 中未发现突变。在一些甲状腺癌中发现磷酸化总 Akt 和 IGF-IR 水平升高。我们的研究结果表明,PI3K/Akt 信号通路在一些甲状腺乳头状癌中被激活。然而,编码该通路大多数介质的基因中的突变尚未被证明是增强激活的主要方式。这些数据表明,PI3K/Akt 介导的信号转导在甲状腺乳头状瘤中可能发挥作用。

相似文献

1
Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.希腊的甲状腺乳头癌中 PI3K/Akt 通路的突变和免疫组化研究。
Endocr Pathol. 2010 Jun;21(2):90-100. doi: 10.1007/s12022-010-9112-0.
2
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.全面的免疫组化和分子方法研究膀胱尿路上皮癌中的 PI3K/AKT/mTOR(磷酸肌醇 3-激酶/v-akt 鼠胸腺瘤病毒致癌基因/雷帕霉素的哺乳动物靶标)通路。
BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.
3
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.肺癌中 PI3K/AKT/mTOR 通路的详细免疫组化分析:与 PIK3CA、AKT1、K-RAS 或 PTEN 基因突变状态及临床病理特征的相关性。
Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.
4
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.磷脂酰肌醇-3激酶催化亚基α(PIK3CA)突变、磷酸酶和张力蛋白同源物、人表皮生长因子受体2以及胰岛素样生长因子1受体与绝经后乳腺癌患者的他莫昔芬辅助治疗耐药性
Breast Cancer Res. 2014 Jan 27;16(1):R13. doi: 10.1186/bcr3606.
5
PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.PI3K/AKT信号通路及其在甲状腺癌中的介质
Mol Diagn Ther. 2016 Feb;20(1):13-26. doi: 10.1007/s40291-015-0175-y.
6
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.甲状腺肿瘤中磷脂酰肌醇-3-激酶/蛋白激酶B通路基因改变的高发生率及相互排斥性
J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90. doi: 10.1210/jc.2006-2019. Epub 2007 Apr 10.
7
The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.LKB1对头颈部癌中与PTEN和PIK3CA相关的PI3K/Akt信号通路激活的影响
Clin Otolaryngol. 2015 Dec;40(6):622-8. doi: 10.1111/coa.12427.
8
Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.PI3K/Akt 通路在黏液样/圆细胞脂肪肉瘤中的作用。
Mod Pathol. 2012 Feb;25(2):212-21. doi: 10.1038/modpathol.2011.148. Epub 2011 Oct 21.
9
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.乳腺癌中PI3K/AKT信号通路基因的突变支持了它们作为乳腺癌侵袭性生物标志物的潜在重要性。
Virchows Arch. 2016 Jul;469(1):35-43. doi: 10.1007/s00428-016-1938-5. Epub 2016 Apr 8.
10
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.子宫内膜癌中PI3K-AKT和p53的伴随改变与预后不良相关。
Mod Pathol. 2009 Apr;22(4):522-9. doi: 10.1038/modpathol.2009.5. Epub 2009 Feb 20.

引用本文的文献

1
IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review.IGF 生物调节系统在甲状腺良恶性结节性疾病中的作用:系统综述。
In Vivo. 2020 Nov-Dec;34(6):3069-3091. doi: 10.21873/invivo.12141.
2
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.儿童和成人甲状腺癌中GPCR介导的PI3K途径突变
Oncotarget. 2019 Jun 25;10(41):4107-4124. doi: 10.18632/oncotarget.26993.
3
Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.

本文引用的文献

1
Silent (synonymous) SNPs: should we care about them?沉默(同义)单核苷酸多态性:我们应该关注它们吗?
Methods Mol Biol. 2009;578:23-39. doi: 10.1007/978-1-60327-411-1_2.
2
Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer.磷酸化胰岛素样生长因子-I受体在人甲状腺癌组织学亚型中的表达及其临床病理意义
Exp Biol Med (Maywood). 2009 Apr;234(4):372-86. doi: 10.3181/0809-RM-284. Epub 2009 Jan 28.
3
RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
共存的甲状腺乳头状癌和间变性癌的分子改变:TERT 突变作为转化的独立危险因素的鉴定。
Mod Pathol. 2017 Nov;30(11):1527-1537. doi: 10.1038/modpathol.2017.75. Epub 2017 Jul 21.
4
The PI3K/Akt Pathway in Tumors of Endocrine Tissues.内分泌组织肿瘤中的PI3K/Akt信号通路
Front Endocrinol (Lausanne). 2016 Jan 11;6:188. doi: 10.3389/fendo.2015.00188. eCollection 2015.
5
PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.PI3K/AKT信号通路及其在甲状腺癌中的介质
Mol Diagn Ther. 2016 Feb;20(1):13-26. doi: 10.1007/s40291-015-0175-y.
6
PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma.PTEN缺失与中东乳头状甲状腺癌的滤泡变体相关。
Br J Cancer. 2015 Jun 9;112(12):1938-43. doi: 10.1038/bjc.2015.169. Epub 2015 May 19.
7
Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.PTEN、PI3K、MTOR和KRAS表达的评估及其与分化型甲状腺癌的临床和预后相关性
Contemp Oncol (Pozn). 2014;18(4):234-40. doi: 10.5114/wo.2014.43803. Epub 2014 Jul 4.
8
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.甲状腺乳头状癌晚期伴发RAS、RET/PTC或BRAF基因突变。
Thyroid. 2014 Aug;24(8):1256-66. doi: 10.1089/thy.2013.0610. Epub 2014 Jun 10.
9
Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.尤因肉瘤中信号通路蛋白定量策略的比较评估
Appl Immunohistochem Mol Morphol. 2014 Sep;22(8):593-9. doi: 10.1097/PAI.0b013e3182a8d4bb.
10
Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population.在韩国人群中,免疫组织化学标志物与 BRAF 突变状态与甲状腺乳头状癌的组织学变异相关。
J Korean Med Sci. 2013 Apr;28(4):534-41. doi: 10.3346/jkms.2013.28.4.534. Epub 2013 Mar 27.
在遭受高辐射剂量的原子弹爆炸幸存者中,RET/PTC重排优先发生于甲状腺乳头状癌。
Cancer Res. 2008 Sep 1;68(17):7176-82. doi: 10.1158/0008-5472.CAN-08-0293.
4
Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model.甲状腺癌、甲状腺炎与膳食碘:基于阿根廷萨尔塔模型的综述
Endocr Pathol. 2008 Winter;19(4):209-20. doi: 10.1007/s12022-008-9038-y.
5
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.甲状腺肿瘤中磷脂酰肌醇3激酶途径的失调。
Endocrinol Metab Clin North Am. 2008 Jun;37(2):375-87, viii-ix. doi: 10.1016/j.ecl.2008.01.001.
6
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.间变性甲状腺癌中的磷脂酰肌醇3激酶/蛋白激酶B及Ras/Raf-丝裂原活化蛋白激酶通路突变
J Clin Endocrinol Metab. 2008 Jan;93(1):278-84. doi: 10.1210/jc.2007-1076. Epub 2007 Nov 7.
7
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.沉默多态性的启示:它们如何影响药物基因组学及癌症治疗
Cancer Res. 2007 Oct 15;67(20):9609-12. doi: 10.1158/0008-5472.CAN-07-2377.
8
Silent SNPs: impact on gene function and phenotype.沉默单核苷酸多态性:对基因功能和表型的影响。
Pharmacogenomics. 2007 Aug;8(8):1075-80. doi: 10.2217/14622416.8.8.1075.
9
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.磷酸肌醇3-激酶催化亚基中两类癌症突变的机制
Science. 2007 Jul 13;317(5835):239-42. doi: 10.1126/science.1135394.
10
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.甲状腺肿瘤中磷脂酰肌醇-3-激酶/蛋白激酶B通路基因改变的高发生率及相互排斥性
J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90. doi: 10.1210/jc.2006-2019. Epub 2007 Apr 10.